HERBORIUM GROUP, INC. Inactive Instrument
Herborium Group, Inc. Stock Other OTC
Equities
HBRM
US42703A2087
Biotechnology & Medical Research
Financials (USD)
| Sales 2010 | 262K | Sales 2011 | 234K | Capitalization | 210K |
|---|---|---|---|---|---|
| Net income 2010 | - | Net income 2011 | - | EV / Sales 2010 | 10.7 x |
| Net Debt 2010 | 588K | Net Debt 2011 | 621K | EV / Sales 2011 | 3.55 x |
| P/E ratio 2010 |
-4.35
x | P/E ratio 2011 |
-0.97
x | Employees | - |
| Yield 2010 * |
-
| Yield 2011 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Agnes Olszewski
CEO | Chief Executive Officer | 67 | 02-06-03 |
John Donahue
AUD | Comptroller/Controller/Auditor | 74 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Agnes Olszewski
CEO | Chief Executive Officer | 67 | 02-06-03 |
Herborium Group, Inc. is a developer, licensor and marketer of herbal ingredient-based medicines and wellness products. The Company's flagship product, AcnEase is an herbal, oral treatment for patients with acne or rosacea. The Company serves clients worldwide. It is engaged in the development of a series of the artificial intelligence (AI)-based content products related to dermatological and beauty space. In addition to AcnEase, the Company has secured a pipeline of product candidates. The products include protein skin bar and adjunct cutting age skincare products based on stem cell technology. it is also ready for commercialization of new products line of natural sexual health and performance enhancing products for men and women. The Company owns all formulations for its proprietary products.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.49% | 96.73B | |
| -1.86% | 21.31B | |
| -16.61% | 21.21B | |
| -5.80% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
